(Total Views: 332)
Posted On: 05/05/2021 9:12:21 PM
Post# of 36564
That article must be why we've seen such a surge in our share price...LOL
"Bintai Kinden’s vaccine candidate is progressing relatively slowly."
"It is worth noting that Bintai Kinden’s vaccine partner Generex, which has not started Phase 1 clinical trials, has seen its share price retreat 62.2% from its peak in May last year."
https://www.theedgemarkets.com/article/cut-ou...k-new-role
"Bintai Kinden’s vaccine candidate is progressing relatively slowly."
"It is worth noting that Bintai Kinden’s vaccine partner Generex, which has not started Phase 1 clinical trials, has seen its share price retreat 62.2% from its peak in May last year."
https://www.theedgemarkets.com/article/cut-ou...k-new-role
(0)
(0)
